Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines

Molecular Cancer Research

Volumn 5, Issue 6, 2007, Pages 641-653

  Gómez Martínez, Angeles ^a   García Morales, Pilar ^a   Carrato, Alfredo ^a,b   Castro Galache, María D ^a   Soto, José L ^b   Carrasco García, Estefanía ^a   García Bautista, Miriam ^b   Guaraz, Patricia ^b   Ferragut, José A ^a   Saceda, Miguel ^a,b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA;

5' UNTRANSLATED REGION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN HT29; CELL STRAIN K 562; CELL STRAIN MCF 7; COLON CARCINOMA; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; TRANSLATION REGULATION; WILD TYPE;

5' UNTRANSLATED REGIONS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; K562 CELLS; MODELS, GENETIC; NUCLEIC ACID CONFORMATION; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROMOTER REGIONS (GENETICS); RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER;

EID: 34250795145     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0177     Document Type: Article

References (32)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
2. Ambudkar SV, Dey SHCA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
4. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12:450-8.
5. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1-6.
6. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000;38:1-11.
7. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66.
8. Hu Z, Jin S, Scotto KW. Transcriptional activation of the MDR1gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000;275:2979-85.
9. Schondorf T, Kurbacher CM, Gohring UJ, et al. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 2002;22:2199-203.
10. Vilaboa NE, Galan A, Troyano A, de Blas E, Aller P. Regulation of multidrug resistance 1(MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000;275:24970-6.
11. Ziemann C, Burkle A, Kahl GF, Hirsch-Ernst KI. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis 1999;20:407-14.
12. Chen GK, Sale S, Tan T, Ermoian RP, Sikic BI. CCAAT/enhancer-binding protein β (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 2004;65:906-16.
13. Kuwano M, Uchiumi T, Hayakawa H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003;94:9-14.
14. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
15. Strauss BE, Shivakumar C, Deb SP, Deb S, Haas M. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 1995;217:825-31.
16. Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 1995;217:333-40.
17. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998;18:4377-84.
18. He LZ, Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321-30.
19. Yuan Y, Zhang J, Scanlon KJ, Lu Z, Qi G. Reversion of multidrug resistance in the P-glycoprotein positive breast cancer cell line (MCF-7/ADR) by introduction of hammerhead ribozyme. Chin Med Sci J 1998;13:24-8.
20. Budworth J, Gant TW, Gescher A. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Br J Cancer 1997;75:1330-5.
21. Ogretmen B, Safa AR. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-κ B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 1999;38:2189-99.
22. Sharma D, Southworth DR, Green R. EF-G-independent reactivity of a pretranslocation-state ribosome complex with the aminoacyl tRNA substrate puromycin supports an intermediate (hybrid) state of tRNA binding. RNA 2004;10:102-13.
23. Rimet O, Mirrione A, Barra Y. Multidrug-resistant phenotype influences the differentiation of a human colon carcinoma cell line. Biochem Biophys Res Commun 1999;259:43-9.
24. Raguz S, Tamburo DB, Tripuraneni G, et al Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res 2004;10:2776-83.
25. Castro-Galache MD, Ferragut JA, Barbera VM, et al. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int J Cancer 2003;104:579-86.
26. Garcia-Morales P, Castro-Galache MD, Menendez-Gutierrez MP, Garcia-Poveda E, Ferragut JA, Saceda M. Trichostatin A effects in different drug-resistant tumor cell lines. Av Diabetol 2002;18:175-9.
27. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 2002;99:292-8.
28. Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003;278:10344-52.
29. Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001;7:4096-101.
30. Aleu J, Ivorra I, Lejarreta M, Gonzalez-Ros JM, Morales A, Ferragut JA. Functional incorporation of P-glycoprotein into Xenopus oocyte plasma membrane fails to elicit a swelling-evoked conductance. Biochem Biophys Res Commun 1997;237:407-12.
31. Soto F, Planells-Cases R, Canaves JM, et al. Possible coexistence of two independent mechanisms contributing to anthracycline resistance in leukaemia P388 cells. Eur J Cancer 1993;29:2144-50.
32. Soto F, Canaves JM, Gonzalez-Ros JM, Ferragut JA. Rapid kinetics of the interaction between daunomycin and drug-sensitive or drug-resistant P388 leukemia cells. FEBS Lett 1992;301:119-23.